Injection 60mg/mL pre-filled syringe

Licensed for treatment of postmenopausal osteoporosis in women at increased risk of fractures and for the treatment of bone loss associated with hormone ablation in men with prostate cancer. See NICE guideline TA204

Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture

Injection 120mg vial

Injection 120mg/ml pre-filled syringe

Commissioning arrangements for the supply and administration of denosumab 120mg by Primary Care have been reviewed. LSCMMG have decided to revert to a Red RAG status. However, primary care prescribers should continue to supply denosumab 120mg for existing patients until further local guidance is made available.